ARTICLE SUMMARY:
Led by Boston Scientific veterans and its technology’s co-inventor, Amplitude Vascular Systems is sponsoring the pivotal trial for a novel intravascular lithotripsy system that it believes will make up ground on Shockwave, the Johnson & Johnson subsidiary that established this billion-dollar market.
Amplitude Vascular Systems (AVS) believes its Pulse IVL System can take market share in the expanding intravascular lithotripsy (IVL) space by offering a user-centric, small-footprint system for treating vascular calcium.
Calcium is “literally rock hard,” and therefore makes angioplasty or stenting in those vessels especially difficult, Sean Gilligan, AVS’ chief operations officer, tells MedTech Strategist in an interview. Traditionally, those vessels could only be treated with invasive surgery or atherectomy procedures that mechanically cut or extract the calcium.
